other material
confidence high
sentiment neutral
materiality 0.60
Aileron stops NSCLC trial enrollment after interim data; revises breast cancer trial
Rein Therapeutics, Inc.
- Interim data from 20 patients: ALRN-6924 patients completed 93% of first 4 chemo cycles vs 78% placebo.
- Progression-free survival median 4.6 months on ALRN-6924 vs 3.2 months on placebo.
- Composite primary endpoint: 56% cycles free of Grade ≥3 hematologic toxicities vs 50% placebo.
- Plans to stop further NSCLC enrollment; apply learnings to breast cancer trial with revised dosing and endpoint.
- Will not further enroll 0.3 mg/kg and 0.6 mg/kg cohorts in breast cancer trial; higher dose to be evaluated.